Janet L. Oblinger, Ph.D.
Affiliations: | Ohio State University, Columbus, Columbus, OH |
Area:
pathobiology of brain cancerGoogle:
"Janet Oblinger"Mean distance: 20037.4
Parents
Sign in to add mentorAllan James Yates | grad student | 2002 | Ohio State | |
(Cell-context-dependent modulation of receptor tyrosine kinases by ganglioside GM1.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Chang LS, Oblinger JL, Burns SS, et al. (2019) Targeting protein translation by rocaglamide and didesmethylrocaglamide to treat MPNST and other sarcomas. Molecular Cancer Therapeutics |
Angus SP, Oblinger JL, Stuhlmiller TJ, et al. (2018) EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. Neuro-Oncology |
Oblinger JL, Burns SS, Huang J, et al. (2017) Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Experimental Neurology |
Oblinger JL, Burns SS, Akhmametyeva EM, et al. (2016) Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas. Neuro-Oncology |
Burns SS, Akhmametyeva EM, Oblinger JL, et al. (2013) Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth. Cancer Research. 73: 792-803 |
Bush ML, Burns SS, Oblinger J, et al. (2012) Treatment of vestibular schwannoma cells with ErbB inhibitors. Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 33: 244-57 |
Jacob A, Oblinger J, Bush ML, et al. (2012) Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas. The Laryngoscope. 122: 174-89 |
Bush ML, Oblinger J, Brendel V, et al. (2011) AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Neuro-Oncology. 13: 983-99 |
Chai G, Liu N, Ma J, et al. (2010) MicroRNA-10b regulates tumorigenesis in neurofibromatosis type 1. Cancer Science. 101: 1997-2004 |
Oblinger JL, Pearl DK, Boardman CL, et al. (2006) Diagnostic and prognostic value of glycosyltransferase mRNA in glioblastoma multiforme patients. Neuropathology and Applied Neurobiology. 32: 410-8 |